Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability

American Heart Journal

Volumn 131, Issue 3, 1996, Pages 472-480

  Pratt, Craig M ^a   Ruberg, Stephen ^b   Morganroth, Joel ^c   McNutt, Bruce ^b   Woodward, James ^b   Harris, Stuart ^d   Ruskin, Jeremy ^e   Moyé, Lemuel ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Marion Merrell Dow Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d South Florida Bioavailability Clinic   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TERFENADINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART ELECTROPHYSIOLOGY; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES;

EID: 0029883856     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90525-6     Document Type: Article

References (22)

1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
2. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
3. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
4. Mathews DR, McNutt B, Okerholm R, Flicker M, McBride G. Torsades de pointes occurring in association with terfenadine use [Letter]. JAMA 1991;266:2375-6.
5. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002-3.
6. Bastecky J, Kvasnicka J, Vortel J, Tauchman M, Wasylivova V. Severe intoxication with antihistaminics complicated by ventricular tachycardia. Intern Med 1990;3:266-9.
7. Bazett HC. An analysis of the time-relations of the electrocardiogram. Heart 1920;7:353-70.
8. Meinert CL. Clinical trials design, conduct and analysis. New York: Oxford University Press, 1986:81-6.
9. Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, Lopez H. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 1993;72:26B-31B.
10. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-6.
11. Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 1985;5:625-31.
12. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RQ, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.
13. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. AM HEART J 198;111:1088-93.
14. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsades de pointes due to quinidine: observations in 31 patients. AM HEART J 1984;107:425-30.
15. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5:515-30.
16. Horowitz LN, Greenspan AM, Spielman SR, Josephson ME. Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities. Circulation 1981;63:1120-8.
17. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. AM HEART J 1987;113: 1470-82.
18. Laks MM. Long QT interval syndrome: a new look at an old electrocardiographic measurement - the power of the computer. Circulation 1990;82:1539-41.
19. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-72.
20. Surawicz B. The QT interval and cardiac arrhythmias. Annu Rev Med 1987;38:81-90.
21. Roden DM. Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol 1988;62:34H-8H.
22. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moyè L. Risk of developing life-threatening ventricular arrhythmias associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994;73:346-52.